<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03576443</url>
  </required_header>
  <id_info>
    <org_study_id>NLG-LBC-07</org_study_id>
    <nct_id>NCT03576443</nct_id>
  </id_info>
  <brief_title>Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma</brief_title>
  <acronym>ILIAD</acronym>
  <official_title>A Phase II Trial of Idelalisib in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nordic Lymphoma Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nordic Lymphoma Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Based on the high response rate in heavily pretreated patients with indolent B-cell&#xD;
      lymphomas, among which it is likely that many have undetected transformed disease, the&#xD;
      investigators hypothesize that idelalisib may also be active in relapsed DLBCL, particularly&#xD;
      of the GCB subtype. Possibly, the efficacy may be related to the presence of specific&#xD;
      mutations within the B-cell receptor pathway.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 7, 2017</start_date>
  <completion_date type="Actual">September 30, 2021</completion_date>
  <primary_completion_date type="Actual">September 30, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate for GCB DLBCL</measure>
    <time_frame>at time of progression, up to 112 weeks from start of treatment</time_frame>
    <description>Overall response rate (ORR) for GCB DLBCL</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Diffuse Large B Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Idelalisib 150 mg x 2 p o, until progression</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Idelalisib</intervention_name>
    <description>Idelalisib 150 mg x 2 p o</description>
    <arm_group_label>Treatment arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age &gt;18 years.&#xD;
&#xD;
          2. Histologically confirmed diffuse large B-cell lymphoma (DLBCL) , including transformed&#xD;
             low grade lymphoma, with either:&#xD;
&#xD;
               1. Refractory disease: defined as disease progression while receiving their most&#xD;
                  recent prior cytotoxic chemotherapy (single-agent immunotherapy as maintenance is&#xD;
                  not considered cytotoxic therapy).&#xD;
&#xD;
               2. Persistent disease: defined as stable disease or partial response at the&#xD;
                  completion of their most recent prior cytotoxic chemotherapy.&#xD;
&#xD;
               3. Relapsed/recurrent disease: defined as complete response at the end of their most&#xD;
                  recent prior cytotoxic chemotherapy with subsequent relapse or disease&#xD;
                  recurrence.&#xD;
&#xD;
          3. Subjects must have received prior rituximab and may have received up to 5 prior&#xD;
             regimens containing cytotoxic chemotherapies.&#xD;
&#xD;
          4. Subjects must not be candidates for high-dose chemotherapy with autologous stem cell&#xD;
             support (ASCT), due to one or more of the following factors: relapse after high dose&#xD;
             chemotherapy, age, comorbid disease, performance status, or persisting toxicities from&#xD;
             prior chemotherapy.&#xD;
&#xD;
          5. Absolute neutrophil count (ANC) &gt;1.0 x 109/L, unless related to bone marrow&#xD;
             infiltration.&#xD;
&#xD;
          6. At least 1 measurable disease lesion that is &gt;1.0 cm in 2 perpendicular dimensions,&#xD;
             with the product diameter &gt;2.25 cm2 by computed tomography (CT) or magnetic resonance&#xD;
             imaging (MRI).&#xD;
&#xD;
          7. Negative serum pregnancy test within 1 week before first treatment if the subject is a&#xD;
             woman of childbearing potential. The use of highly-effective contraception methods*&#xD;
             are required during the study for women of child-bearing potential. Due to the&#xD;
             toxicity of idelalisib, women who will use a hormonal contraceptive must in addition&#xD;
             also use a barrier method, since it is currently unknown whether idelalisib may reduce&#xD;
             the effectiveness of hormonal contraceptives. A woman of childbearing potential is&#xD;
             defined as one who is biologically capable of becoming pregnant.&#xD;
&#xD;
          8. WHO performance status 0 - 3.&#xD;
&#xD;
          9. Written informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior allogeneic hematopoietic stem cell transplant (HSCT).&#xD;
&#xD;
          2. Prior treatment with PI3K inhibitors.&#xD;
&#xD;
          3. Serum total bilirubin ≥ 1.5 x ULN (unless elevated due to Gilbert's syndrome).&#xD;
&#xD;
          4. Serum ALT and AST ˃ 2.5 x ULN.&#xD;
&#xD;
          5. Estimated Creatinine Clearance &lt; 10 ml/min.&#xD;
&#xD;
          6. Known seropositivity for human immunodeficiency virus (HIV).&#xD;
&#xD;
          7. Known history of drug induced liver injury, chronic active hepatitis C (HCV), chronic&#xD;
             active hepatitis B (HBV), alcoholic liver disease, non-alcoholic steatohepatitis,&#xD;
             primary biliary cirrhosis, on-going extra-hepatic obstruction caused by&#xD;
             cholelithiasis, cirrhosis of the liver or portal hypertension.&#xD;
&#xD;
          8. Known history of drug induced pneumonitis.&#xD;
&#xD;
          9. On-going inflammatory bowel disease.&#xD;
&#xD;
         10. Evidence of serious active infection (eg, requiring an intravenous [IV] antibiotic,&#xD;
             antiviral, or antifungal agent), or subjects with a recent history of deep tissue&#xD;
             infections such as fascitis or osteomyelitis.&#xD;
&#xD;
         11. Chemotherapy, cancer immunosuppressive therapy, growth factors (except&#xD;
             erythropoietin), or investigational drugs/devices &lt;10 days before first dose of&#xD;
             investigational product in this study. Subjects receiving high doses of&#xD;
             corticosteroids must have been tapered to a stable dose at least 7 days before the&#xD;
             first dose of investigational product.&#xD;
&#xD;
         12. Pregnant or breastfeeding women.&#xD;
&#xD;
         13. Symptomatic central nervous system (CNS) NHL; a lumbar puncture is not required unless&#xD;
             CNS involvement with NHL is clinically suspected.&#xD;
&#xD;
         14. Unstable or severe uncontrolled medical condition (eg, unstable cardiac function,&#xD;
             unstable pulmonary condition).&#xD;
&#xD;
         15. Concurrent active malignancy other than nonmelanoma skin cancer or carcinoma in situ&#xD;
             of the cervix. Subjects with previous malignancies are eligible provided that they&#xD;
             have been disease free for &gt;2 years.&#xD;
&#xD;
         16. Previous myocardial infarction or pulmonary hypertension &lt;6 months before first dose&#xD;
             of investigational product.&#xD;
&#xD;
         17. History of clinically significant ventricular arrhythmia, prolonged QTc interval or&#xD;
             unexplained syncope.&#xD;
&#xD;
         18. Psychiatric illness or condition which could interfere with their ability to&#xD;
             understand the requirements of the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mats Jerkeman</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Oncology Skåne University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus C</city>
        <zip>8000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Odense University Hospital</name>
      <address>
        <city>Odense</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Halmstad County Hospital</name>
      <address>
        <city>Halmstad</city>
        <zip>30 233</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Linkoping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <zip>141 86</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>April 30, 2018</study_first_submitted>
  <study_first_submitted_qc>July 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 3, 2018</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Idelalisib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

